Skip to main content
Erschienen in: Die Pathologie 5/2020

04.08.2020 | Cholangiokarzinom | Schwerpunkt: Leberpathologie

Cholangiokarzinome – Übersicht zur aktuellen anatomischen, histomorphologischen und morphomolekularen Klassifikation

verfasst von: Prof. Dr. med. Benjamin Goeppert

Erschienen in: Die Pathologie | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Unter dem Begriff Cholangiokarzinom werden diverse maligne epitheliale Neoplasien unterschiedlicher Differenzierung, Ätiologie und Pathogenese zusammengefasst.

Ziel der Arbeit

In dieser Arbeit sollen die Ätiologie, Pathogenese, Diagnostik, Klassifikation und molekulare Alterationen intra- und extrahepatischer Cholangiokarzinome dargestellt werden.

Material und Methoden

Grundlage hierfür sind die derzeit verfügbare Fachliteratur sowie eigene Erkenntnisse.

Ergebnisse und Diskussion

Cholangiokarzinome sind morphologisch und molekular vielgestaltige maligne epitheliale Neoplasien, die ubiquitär im Gallengangsystem entstehen können. Da histologisch und immunhistochemisch breite Überlappungen zu den häufigen metastatischen Absiedelungen in der Leber bestehen, sollte die definitive Diagnose nur im klinischen Kontext gestellt werden. Nach makroanatomischen Kriterien werden Cholangiokarzinome in intrahepatische (iCCA), perihiläre (pCCA) und distale (dCCA) Tumore subklassifiziert. Wie sich durch neuere Untersuchungen abzeichnet, bestehen insbesondere zwischen den iCCA und den extrahepatischen CCA (eCCA, diese umfassen pCCA und dCCA) deutliche molekulare Unterschiede. Zudem konnten mittlerweile morphologisch gut charakterisierte Vorläuferläsionen identifiziert werden, die sich in verschiedenen Häufigkeiten nicht nur der anatomischen Klassifikation, sondern auch distinkten Ätiologien zuordnen lassen. Eine exakte Klassifikation der CCA ist somit essenziell, vor allem im Hinblick auf die Entwicklung innovativer, zielgerichteter Therapieansätze.
Literatur
1.
Zurück zum Zitat Adeva J, Sangro B, Salati M et al (2019) Medical treatment for cholangiocarcinoma. Liver Int 39(Suppl 1):123–142CrossRef Adeva J, Sangro B, Salati M et al (2019) Medical treatment for cholangiocarcinoma. Liver Int 39(Suppl 1):123–142CrossRef
2.
Zurück zum Zitat Albores-Saavedra J, Henson DE, Klimstra DS (2000) Armed Forces Institute of Pathology (AFIP) Atlas; tumors of the gallbladder, extrahepatic bile ducts, and ampulla of vater Albores-Saavedra J, Henson DE, Klimstra DS (2000) Armed Forces Institute of Pathology (AFIP) Atlas; tumors of the gallbladder, extrahepatic bile ducts, and ampulla of vater
3.
Zurück zum Zitat Andersen JB, Spee B, Blechacz BR et al (2012) Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 142:1021–1031CrossRef Andersen JB, Spee B, Blechacz BR et al (2012) Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 142:1021–1031CrossRef
4.
Zurück zum Zitat Arends MJ, Fukayama M, Klimstra DS et al (2019) WHO classification of tumours, digestive system tumours, 5. Aufl. Arends MJ, Fukayama M, Klimstra DS et al (2019) WHO classification of tumours, digestive system tumours, 5. Aufl.
5.
Zurück zum Zitat Banales JM, Cardinale V, Carpino G et al (2016) Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European network for the study of Cholangiocarcinoma (ENS-CCA). Nature reviews. Gastroenterol Hepatol 13:261–280 Banales JM, Cardinale V, Carpino G et al (2016) Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European network for the study of Cholangiocarcinoma (ENS-CCA). Nature reviews. Gastroenterol Hepatol 13:261–280
6.
Zurück zum Zitat Borger DR, Tanabe KK, Fan KC et al (2012) Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 17:72–79CrossRef Borger DR, Tanabe KK, Fan KC et al (2012) Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 17:72–79CrossRef
7.
Zurück zum Zitat Bosman FT, Carneiro F, Hruban RH et al (2010) WHO classification of tumours of the digestive system. International Agency for Research on Cancer (IARC), Lyon, France Bosman FT, Carneiro F, Hruban RH et al (2010) WHO classification of tumours of the digestive system. International Agency for Research on Cancer (IARC), Lyon, France
8.
Zurück zum Zitat Bridgewater J, Galle PR, Khan SA et al (2014) Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 60:1268–1289CrossRef Bridgewater J, Galle PR, Khan SA et al (2014) Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 60:1268–1289CrossRef
9.
Zurück zum Zitat Cardinale V, Carpino G, Reid LM et al (2012) Cholangiocarcinoma: a cancer in search of the right classification. Hepatology 56:1585–1586 (author reply 1586)CrossRef Cardinale V, Carpino G, Reid LM et al (2012) Cholangiocarcinoma: a cancer in search of the right classification. Hepatology 56:1585–1586 (author reply 1586)CrossRef
10.
Zurück zum Zitat Cardinale V, Wang Y, Carpino G et al (2012) Mucin-producing cholangiocarcinoma might derive from biliary tree stem/progenitor cells located in peribiliary glands. Hepatology 55:2041–2042CrossRef Cardinale V, Wang Y, Carpino G et al (2012) Mucin-producing cholangiocarcinoma might derive from biliary tree stem/progenitor cells located in peribiliary glands. Hepatology 55:2041–2042CrossRef
11.
Zurück zum Zitat Chaisaingmongkol J, Budhu A, Dang H et al (2017) Common molecular subtypes among asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell 32:57–70 e53CrossRef Chaisaingmongkol J, Budhu A, Dang H et al (2017) Common molecular subtypes among asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell 32:57–70 e53CrossRef
12.
Zurück zum Zitat Chan-On W, Nairismagi ML, Ong CK et al (2013) Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet 45:1474–1478CrossRef Chan-On W, Nairismagi ML, Ong CK et al (2013) Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet 45:1474–1478CrossRef
13.
Zurück zum Zitat Drilon A, Laetsch TW, Kummar S et al (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378:731–739CrossRef Drilon A, Laetsch TW, Kummar S et al (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378:731–739CrossRef
14.
Zurück zum Zitat Edge SB, Byrd DR (2010) AJCC cancer staging manual, 7. Aufl. Edge SB, Byrd DR (2010) AJCC cancer staging manual, 7. Aufl.
15.
Zurück zum Zitat Fan B, Malato Y, Calvisi DF et al (2012) Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest 122:2911–2915CrossRef Fan B, Malato Y, Calvisi DF et al (2012) Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest 122:2911–2915CrossRef
17.
Zurück zum Zitat Goeppert B, Frauenschuh L, Renner M et al (2014) BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. Mod Pathol 27:1028–1034CrossRef Goeppert B, Frauenschuh L, Renner M et al (2014) BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. Mod Pathol 27:1028–1034CrossRef
18.
Zurück zum Zitat Goeppert B, Konermann C, Schmidt CR et al (2014) Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway. Hepatology 59:544–554CrossRef Goeppert B, Konermann C, Schmidt CR et al (2014) Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway. Hepatology 59:544–554CrossRef
19.
Zurück zum Zitat Goeppert B, Roessler S, Renner M et al (2019) Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma. Br J Cancer 120:109–114CrossRef Goeppert B, Roessler S, Renner M et al (2019) Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma. Br J Cancer 120:109–114CrossRef
20.
Zurück zum Zitat Goeppert B, Toth R, Singer S et al (2019) Integrative analysis defines distinct prognostic subgroups of intrahepatic cholangiocarcinoma. Hepatology 69:2091–2106CrossRef Goeppert B, Toth R, Singer S et al (2019) Integrative analysis defines distinct prognostic subgroups of intrahepatic cholangiocarcinoma. Hepatology 69:2091–2106CrossRef
21.
Zurück zum Zitat Jiao Y, Pawlik TM, Anders RA et al (2013) Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 45:1470–1473CrossRef Jiao Y, Pawlik TM, Anders RA et al (2013) Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 45:1470–1473CrossRef
22.
Zurück zum Zitat Jusakul A, Cutcutache I, Yong CH et al (2017) Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov 7:1116–1135CrossRef Jusakul A, Cutcutache I, Yong CH et al (2017) Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov 7:1116–1135CrossRef
23.
Zurück zum Zitat Kendall T, Verheij J, Gaudio E et al (2019) Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int 39(Suppl 1):7–18CrossRef Kendall T, Verheij J, Gaudio E et al (2019) Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int 39(Suppl 1):7–18CrossRef
24.
Zurück zum Zitat Lowery MA, Ptashkin R, Jordan E et al (2018) Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res 24:4154–4161CrossRef Lowery MA, Ptashkin R, Jordan E et al (2018) Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res 24:4154–4161CrossRef
25.
Zurück zum Zitat Nakamura H, Arai Y, Totoki Y et al (2015) Genomic spectra of biliary tract cancer. Nat Genet 47:1003–1010CrossRef Nakamura H, Arai Y, Totoki Y et al (2015) Genomic spectra of biliary tract cancer. Nat Genet 47:1003–1010CrossRef
26.
Zurück zum Zitat Raggi C, Invernizzi P, Andersen JB (2015) Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts. J Hepatol 62:198–207CrossRef Raggi C, Invernizzi P, Andersen JB (2015) Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts. J Hepatol 62:198–207CrossRef
27.
Zurück zum Zitat Rizvi S, Gores GJ (2013) Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145:1215–1229CrossRef Rizvi S, Gores GJ (2013) Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145:1215–1229CrossRef
28.
Zurück zum Zitat Schlitter AM, Born D, Bettstetter M et al (2014) Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways. Mod Pathol 27:73–86CrossRef Schlitter AM, Born D, Bettstetter M et al (2014) Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways. Mod Pathol 27:73–86CrossRef
29.
Zurück zum Zitat Schlitter AM, Jang KT, Kloppel G et al (2015) Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases. Mod Pathol 28:1249–1264CrossRef Schlitter AM, Jang KT, Kloppel G et al (2015) Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases. Mod Pathol 28:1249–1264CrossRef
30.
Zurück zum Zitat Shaib Y, El-Serag HB (2004) The epidemiology of cholangiocarcinoma. Semin Liver Dis 24:115–125CrossRef Shaib Y, El-Serag HB (2004) The epidemiology of cholangiocarcinoma. Semin Liver Dis 24:115–125CrossRef
31.
Zurück zum Zitat Shaib YH, El-Serag HB, Davila JA et al (2005) Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 128:620–626CrossRef Shaib YH, El-Serag HB, Davila JA et al (2005) Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 128:620–626CrossRef
32.
Zurück zum Zitat Sia D, Hoshida Y, Villanueva A et al (2013) Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 144:829–840CrossRef Sia D, Hoshida Y, Villanueva A et al (2013) Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 144:829–840CrossRef
33.
Zurück zum Zitat Sipos B, Henopp T (2011) Precursor lesions of pancreatobiliary cancer. Pathologe 32(Suppl 2):224–231CrossRef Sipos B, Henopp T (2011) Precursor lesions of pancreatobiliary cancer. Pathologe 32(Suppl 2):224–231CrossRef
34.
Zurück zum Zitat Tyson GL, El-Serag HB (2011) Risk factors for cholangiocarcinoma. Hepatology 54:173–184CrossRef Tyson GL, El-Serag HB (2011) Risk factors for cholangiocarcinoma. Hepatology 54:173–184CrossRef
35.
Zurück zum Zitat Tyson GL, Ilyas JA, Duan Z et al (2014) Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification. Dig Dis Sci 59:3103–3110CrossRef Tyson GL, Ilyas JA, Duan Z et al (2014) Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification. Dig Dis Sci 59:3103–3110CrossRef
36.
Zurück zum Zitat Walter D, Ferstl P, Waidmann O et al (2019) Cholangiocarcinoma in Germany: epidemiologic trends and impact of misclassification. Liver Int 39:316–323CrossRef Walter D, Ferstl P, Waidmann O et al (2019) Cholangiocarcinoma in Germany: epidemiologic trends and impact of misclassification. Liver Int 39:316–323CrossRef
37.
Zurück zum Zitat Wardell CP, Fujita M, Yamada T et al (2018) Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J Hepatol 68:959–969CrossRef Wardell CP, Fujita M, Yamada T et al (2018) Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J Hepatol 68:959–969CrossRef
38.
Zurück zum Zitat Zen Y, Adsay NV, Bardadin K et al (2007) Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol 20:701–709CrossRef Zen Y, Adsay NV, Bardadin K et al (2007) Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol 20:701–709CrossRef
39.
Zurück zum Zitat Zen Y, Fujii T, Itatsu K et al (2006) Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology 44:1333–1343CrossRef Zen Y, Fujii T, Itatsu K et al (2006) Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology 44:1333–1343CrossRef
Metadaten
Titel
Cholangiokarzinome – Übersicht zur aktuellen anatomischen, histomorphologischen und morphomolekularen Klassifikation
verfasst von
Prof. Dr. med. Benjamin Goeppert
Publikationsdatum
04.08.2020
Verlag
Springer Medizin
Erschienen in
Die Pathologie / Ausgabe 5/2020
Print ISSN: 2731-7188
Elektronische ISSN: 2731-7196
DOI
https://doi.org/10.1007/s00292-020-00808-6

Weitere Artikel der Ausgabe 5/2020

Die Pathologie 5/2020 Zur Ausgabe

Schwerpunkt: Leberpathologie

Autoimmune Lebererkrankungen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.